These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 14739526)

  • 1. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
    Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
    Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.
    Bergamaschi S; Ronchi CL; Giavoli C; Ferrante E; Verrua E; Ferrari DI; Lania A; Rusconi R; Spada A; Beck-Peccoz P
    Horm Res Paediatr; 2010; 73(1):74-9. PubMed ID: 20190543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary octreotide LAR therapy in GH-secreting pituitary adenoma.
    Harinarayan CV
    J Indian Med Assoc; 2004 May; 102(5):258, 260-1. PubMed ID: 15636029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma.
    Maheshwari HG; Prezant TR; Herman-Bonert V; Shahinian H; Kovacs K; Melmed S
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3409-16. PubMed ID: 10999842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gs alpha mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome.
    Dötsch J; Kiess W; Hänze J; Repp R; Lüdecke D; Blum WF; Rascher W
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3839-42. PubMed ID: 8923825
    [No Abstract]   [Full Text] [Related]  

  • 9. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
    Müssig K; Gallwitz B; Honegger J; Strasburger CJ; Bidlingmaier M; Machicao F; Bornemann A; Ranke MB; Häring HU; Petersenn S
    Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):198-202. PubMed ID: 17427111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous remission of acromegaly or gigantism due to subclinical apoplexy of pituitary growth hormone adenoma.
    Wang XL; Dou JT; Lü ZH; Zhong WW; Ba JM; Jin D; Lu JM; Pan CY; Mu YM
    Chin Med J (Engl); 2011 Nov; 124(22):3820-3. PubMed ID: 22340248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
    Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
    Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
    Tajima T; Tsubaki J; Ishizu K; Jo W; Ishi N; Fujieda K
    Endocr J; 2008 Jul; 55(3):595-9. PubMed ID: 18445999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gigantism with pituitary macroadenoma: an unusual variant of McCune-Albright syndrome.
    Queirolo S; Gallarotti F; Capuano E; Garrè ML; Spaziante R; Di Battista E
    J Pediatr Endocrinol Metab; 2009 Feb; 22(2):177-9. PubMed ID: 19449675
    [No Abstract]   [Full Text] [Related]  

  • 17. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation.
    Zimmerman D; Young WF; Ebersold MJ; Scheithauer BW; Kovacs K; Horvath E; Whitaker MD; Eberhardt NL; Downs TR; Frohman LA
    J Clin Endocrinol Metab; 1993 Jan; 76(1):216-22. PubMed ID: 8421089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic abnormalities of somatostatin receptors in pituitary tumors.
    Lania A; Mantovani G; Spada A
    Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
    Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acromegaly associated with McCune-Albright syndrome].
    Tóth M; Töke J; Kiss E; Bernád I; Miheller P; Szücs N; Rácz K
    Orv Hetil; 2002 May; 143(19 Suppl):1070-3. PubMed ID: 12063863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.